Back to overview
JULIET: Subgroup data
Median age
years
(22-76)1,2
%
were ≥65 years1
ORR
ORR in patients older or younger than 65 years
(40.3 months median follow-up)1
OS
OS in patients older or younger than 65 years
(19 months median follow-up)3
- References: 1. Schuster SJ et al. Lancet Oncol 2021;22(10):1403–1415.
- 2. Schuster SJ et al. N Engl J Med. 2019;380(1):45–56.
- 3. Schuster SJ et al. Presented at ASH 2018.
%
of patients in JULIET had double- or triple-hit rearrangement: MYC plus BCL2, BCL6, or both1
ORR
ORR in patients with or without double or triple-hit rearrangement (40.3 months median follow-up)1
- Reference: 1. Schuster SJ et al. Lancet Oncol 2021;22(10):1403–1415.
%
of patients in JULIET had been treated with 3 or more prior therapies1
ORR
ORR in patients treated with ≤2 and >2 prior lines (40.3 months median follow-up)1
- Reference: 1. Schuster SJ et al. Lancet Oncol 2021;22(10):1403–1415.
55%
of patients in JULIET were refractory to their last therapy1
ORR
ORR in refractory and relapsed patients
(40.3 months median follow-up)1
OS
OS in refractory and relapsed patients
(19 months median follow-up)2
- References: 1. Schuster SJ et al. Lancet Oncol 2021;22(10):1403–1415.
- 2. Schuster SJ et al. Presented at ASH 2018.
%
of patients in JULIET had received prior ASCT1
ORR in patients who had or had not received prior ASCT (40.3 months median follow-up)1
- Reference: 1. Schuster SJ et al. Lancet Oncol 2021;22(10):1403–1415.
Patient
summary
Your patient summary will be shown here as you save you patient selections
This is where your patient summary will be shown. If you would like more tailored data, create a patient profile
Start a patient profile3L+ DLBCL PATIENT
Patient profile
- Incomplete
Treatment history
- Incomplete
Treatment choice
- Incomplete